Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival

Lynn A. Fussner, Vivek N. Iyer, Rodrigo Cartin‐Ceba, Grace Lin, Kymberly D. Watt, Michael J. Krowka – 16 June 2015 – Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are pulmonary vascular complications of portal hypertension with divergent clinicopathologic features and management. The presence of intrapulmonary vascular dilatations (IPVDs), detected by agitated saline contrast‐enhanced transthoracic echocardiography (cTTE), is an essential feature of HPS but is not typically characteristic of POPH.

Receptor interacting protein kinase 1 mediates murine acetaminophen toxicity independent of the necrosome and not through necroptosis

Lily Dara, Heather Johnson, Jo Suda, Sanda Win, William Gaarde, Derick Han, Neil Kaplowitz – 16 June 2015 – Although necrosis in the acetaminophen (APAP) model is known to be regulated by c‐Jun NH2‐terminal kinase (JNK) through interaction with mitochondria, the role of necroptosis through receptor‐interacting proteins 1 and 3 (RIPK1 and RIPK3) has also been suggested. Our aim was to determine the relationship between these two mechanisms of cell death.

Liver transplantation for alveolar echinococcosis in an endemic region

Bulent Aydinli, Gurkan Ozturk, Sukru Arslan, Mecit Kantarci, Onder Tan, Ali Ahıskalioglu, Kemalettin Özden, Abdurrahim Colak – 13 June 2015 – Alveolar echinococcosis (AE) is a chronic disease caused by ingestion of the eggs of the parasitic cestode Echinococcosis multilocularis (EM). In severe cases, liver transplantation (LT) may represent the only possibility of survival and cure. Patients undergoing LT associated with hepatic AE at our institution between April 2011 and October 2014 were investigated retrospectively.

Transarterial chemoembolization with drug‐eluting beads is effective for the maintenance of the Milan‐in status in patients with a small hepatocellular carcinoma

Matteo Angelo Manini, Angelo Sangiovanni, Laura Martinetti, Davide Viganò, Vincenzo La Mura, Alessio Aghemo, Massimo Iavarone, Silvia Crespi, Antonio Nicolini, Massimo Colombo – 13 June 2015 – Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). We explored the efficacy of TACE with drug‐eluting beads (DEB) in BCLC A patients.

The corrected donor age for hepatitis C virus–infected liver transplant recipients

Melisa Dirchwolf, Jennifer L. Dodge, Jane Gralla, Kiran M. Bambha, Trevor Nydam, Kenneth W. Hung, Hugo R. Rosen, Sandy Feng, Norah A. Terrault, Scott W. Biggins – 13 June 2015 – Donor age has become the dominant donor factor used to predict graft failure (GF) after liver transplantation (LT) in hepatitis C virus (HCV) recipients. The purpose of this study was to develop and validate a model of corrected donor age (CDA) for HCV LT recipients that transforms the risk of other donor factors into the scale of donor age.

Apolipoprotein E and protection against hepatitis E viral infection in American non‐Hispanic blacks

Lyna Zhang, Ajay Yesupriya, Man‐Huei Chang, Eyasu Teshale, Chong‐Gee Teo – 11 June 2015 – Hepatitis E viral (HEV) infection imposes a heavy health burden worldwide and is common in the United States. Previous investigations of risks addressed environmental and host behavioral/lifestyle factors, but host genetic factors have not been examined.

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

Bashar A. Aqel, Surakit Pungpapong, Michael Leise, K. Tuesday Werner, Amy E. Chervenak, Kymberly D. Watt, Jennifer L. Murphy, Kristen Ryland, Andrew P. Keaveny, Ryan McLemore, Hugo E. Vargas – 11 June 2015 – Interferon (IFN)‐free regimens are needed to treat hepatitis C virus (HCV) infection. Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).

Hepatitis C virus drug resistance–associated substitutions: State of the art summary

Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot‐Matias, Veronica Miller – 10 June 2015 – Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions.

Subscribe to